Greater tau load and reduced cortical thickness in APOE ε4-negative Alzheimer’s disease: a cohort study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1758-9193
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Greater tau load and reduced cortical thickness in APOE ε4-negative Alzheimer’s disease: a cohort study ; volume:10 ; number:1 ; day:7 ; month:8 ; year:2018 ; pages:1-12 ; date:12.2018
Alzheimer's research & therapy ; 10, Heft 1 (7.8.2018), 1-12, 12.2018
- Urheber
- Beteiligte Personen und Organisationen
-
Ossenkoppele, Rik
Smith, Ruben
Strandberg, Olof
Ohlsson, Tomas
Jögi, Jonas
Palmqvist, Sebastian
Stomrud, Erik
Hansson, Oskar
SpringerLink (Online service)
- DOI
-
10.1186/s13195-018-0403-x
- URN
-
urn:nbn:de:101:1-2018100723394015521749
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:21 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Mattsson-Carlgren, Niklas
- Ossenkoppele, Rik
- Smith, Ruben
- Strandberg, Olof
- Ohlsson, Tomas
- Jögi, Jonas
- Palmqvist, Sebastian
- Stomrud, Erik
- Hansson, Oskar
- SpringerLink (Online service)
Ähnliche Objekte (12)
Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease
Fluid biomarkers in Alzheimer’s disease – current concepts
CSF biomarkers for Alzheimer's pathology and the effect size of APOE ε4
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Increased plasma and brain immunoglobulin A in Alzheimer’s disease is lost in apolipoprotein E ε4 carriers
Serum proteomics reveal APOE-ε4-dependent and APOE-ε4-independent protein signatures in Alzheimer’s disease
Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer’s disease: an observational study
Blood‐based biomarkers for Alzheimer's disease
[18F]Flortaucipir distinguishes Alzheimer’s disease from progressive supranuclear palsy pathology in a mixed-pathology case
Author Correction: Serum proteomics reveal APOE-ε4-dependent and APOE-ε4-independent protein signatures in Alzheimer’s disease
Cognitively normal women with Alzheimer’s disease proteinopathy show relative preservation of memory but not of hippocampal volume
Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease
Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease
Fluid biomarkers in Alzheimer’s disease – current concepts
CSF biomarkers for Alzheimer's pathology and the effect size of APOE ε4
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Increased plasma and brain immunoglobulin A in Alzheimer’s disease is lost in apolipoprotein E ε4 carriers
Serum proteomics reveal APOE-ε4-dependent and APOE-ε4-independent protein signatures in Alzheimer’s disease
Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer’s disease: an observational study
Blood‐based biomarkers for Alzheimer's disease
[18F]Flortaucipir distinguishes Alzheimer’s disease from progressive supranuclear palsy pathology in a mixed-pathology case
Author Correction: Serum proteomics reveal APOE-ε4-dependent and APOE-ε4-independent protein signatures in Alzheimer’s disease
Cognitively normal women with Alzheimer’s disease proteinopathy show relative preservation of memory but not of hippocampal volume
Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease
Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease
Fluid biomarkers in Alzheimer’s disease – current concepts
CSF biomarkers for Alzheimer's pathology and the effect size of APOE ε4
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Increased plasma and brain immunoglobulin A in Alzheimer’s disease is lost in apolipoprotein E ε4 carriers
Serum proteomics reveal APOE-ε4-dependent and APOE-ε4-independent protein signatures in Alzheimer’s disease
Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer’s disease: an observational study
Blood‐based biomarkers for Alzheimer's disease
[18F]Flortaucipir distinguishes Alzheimer’s disease from progressive supranuclear palsy pathology in a mixed-pathology case
Author Correction: Serum proteomics reveal APOE-ε4-dependent and APOE-ε4-independent protein signatures in Alzheimer’s disease
Cognitively normal women with Alzheimer’s disease proteinopathy show relative preservation of memory but not of hippocampal volume